Search

Zentalis Pharmaceuticals Inc

Lezárt

2.6 -5.45

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

2.58

Maximum

2.76

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+194.83% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-85M

246M

Előző nyitás

8.05

Előző zárás

2.6

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 30. 23:56 UTC

Correlated Moves

Entegris Inc's shares rose in after-market hours, maintaining stability with little change since Wednesday's close, positioned above its 20-day moving average.

2026. szept. 30. 23:56 UTC

Eastman Chemical Co's shares advanced modestly in after-market trading, recovering from an initial dip and closing above its 20-day moving average.

2026. szept. 30. 23:56 UTC

Rambus Inc is seeing a slight uptick in after-market trading, recovering from earlier declines and remaining well above its 20-day moving average.

2026. szept. 30. 23:55 UTC

RingCentral Inc's shares are modestly higher in after-market trading, remaining above the 20-day moving average despite earlier declines during the session.

2026. szept. 30. 23:55 UTC

Arbor Realty Trust Inc is trading modestly higher in after-market hours, recovering from an initial dip to a cumulative return of 0.51%.

2026. szept. 30. 23:55 UTC

Peloton Interactive Inc. is experiencing a modest decline in after-market trading, nearing its lowest point of the day amid broader market pressures.

2026. szept. 30. 23:55 UTC

Hartford Insurance Group Inc declined in after-market hours, continuing a downward trend from Wednesday's close, amid broader market conditions and below its 20-day moving average.

2026. szept. 30. 23:55 UTC

DHT Holdings Inc has remained roughly flat in after-market hours, fluctuating slightly while staying above its 20-day moving average following recent higher closes.

2026. szept. 30. 23:55 UTC

Ready Capital Corp advanced in after-market trading on Wednesday, despite a recent trend of lower daily closes and being significantly below its 20-day moving average.

2026. szept. 30. 23:55 UTC

Dow Inc. traded modestly higher in after-market hours on Wednesday, recovering from an initial dip but remains 4.85% below its 20-day moving average.

2026. szept. 30. 23:52 UTC

South Korea's S&P Global Manufacturing PMI release on October 1, 2026, is anticipated to reveal cautious insights amid declining industrial production and mixed regional economic signals.

2026. szept. 30. 23:52 UTC

South Korea's October export growth forecasted at 0.617%, down from August's 68.7% amid cautious market sentiment and rising import expectations of 21.5%.

2026. szept. 30. 23:52 UTC

Bank of Japan to release Q3 Tankan Index on September 30, with market expectations set at a stable forecast of 25.0 amid cautious optimism among large manufacturers.

2026. szept. 30. 23:52 UTC

ISM Manufacturing PMI for September 2026 set to release on October 1, with a forecast of 55.0 indicating continued sector expansion amid mixed but optimistic U.S. economic sentiment.

2026. szept. 30. 23:52 UTC

Market Awaits ISM Manufacturing Employment Data Release Amid Mixed Economic Signals and Optimism from Other Sectors.

2026. szept. 30. 23:52 UTC

Market Awaits BoJ Summary of Opinions on Monetary Policy Amid Inflation Concerns, Scheduled for September 30, 2026.

2026. szept. 30. 23:52 UTC

Japan's Current Account Release on October 7, 2026, Expected to Influence Investor Sentiment Amidst Macroeconomic Volatility.

2026. szept. 30. 23:51 UTC

Bank of America Corp is moving higher in after-market trading, supported by a broader market rally and stronger-than-expected economic data, including GDP and job growth.

2026. szept. 30. 23:51 UTC

Applied Materials Inc is moving higher in after-market trading, reflecting positive macroeconomic indicators, including an upward revision of U.S. GDP growth for Q2 to 2.2%.

2026. szept. 30. 23:51 UTC

CrowdStrike Holdings Inc is trading modestly lower in after-market hours, following a notable decline from early highs earlier in the session.

2026. szept. 30. 23:51 UTC

ICU Medical Inc is trading higher in after-market hours, supported by positive economic indicators, including a revised U.S. GDP growth rate of 2.2% for Q2.

2026. szept. 30. 23:51 UTC

Social Media

McCormick & Company shares are advancing in after-market trading ahead of earnings, reflecting broader market gains driven by strong economic data.

2026. szept. 30. 23:51 UTC

UWM Holdings Corp is higher in after-market trading, reflecting positive macroeconomic indicators, including an upward revision of Q2 U.S. GDP growth to 2.2%.

2026. szept. 30. 23:51 UTC

Camden Property Trust advanced modestly in after-market trading, recovering from an early low to a late afternoon high amid ongoing volatility.

2026. szept. 30. 23:50 UTC

Healthcare Services Group Inc is trading higher in after-market hours, supported by positive economic indicators and gains across the broader market.

2026. szept. 30. 23:50 UTC

Tilray Brands Inc is trading modestly lower in after-market hours, continuing a trend of declines following three consecutive lower daily finishes.

2026. szept. 30. 23:50 UTC

Penumbra Inc is lower in after-market trading, recovering slightly from earlier losses but remaining near the lower end of its one-month range.

2026. szept. 30. 23:50 UTC

Williams-Sonoma Inc is trading modestly higher in after-market hours, supported by a significant upward movement in the broader market.

2026. szept. 30. 23:50 UTC

Crown Castle Inc is experiencing a higher price movement in after-market trading, reflecting an upward trend in the broader market despite remaining below its 20-day moving average.

2026. szept. 30. 23:50 UTC

Booz Allen Hamilton Holding Corp is rising in after-market trading, supported by stronger-than-expected U.S. GDP growth and private sector job growth in September.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

194.83% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.167 USD  194.83%

Magas 11 USD

Alacsony 5 USD

7 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

7 ratings

5

Vétel

2

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.